GlassScriptPhysician profile
Pulin P Patel
NPI 1710950951
$430,638.19
in general payments reported to CMS, 2019-2025
46 companies · $146K in 2025
The $146K reported for 2025 was more than what 99% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $20K · 2021: $28K · 2022: $48K · 2023: $49K · 2024: $98K · 2025: $146K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $228K · Consulting Fee: $25K · Food and Beverage: $22K · Travel and Lodging: $18K · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $228,086.83 |
| Consulting Fee | $24,600.32 |
| Food and Beverage | $22,488.23 |
| Travel and Lodging | $17,938.69 |
| Education | $189.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $128,243.26 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $105,233.69 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $88,759.72 | 2019-2025 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $31,431.04 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $22,410.11 | 2020-2025 | Cuvitru, Hyqvia, Eohilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13,298.89 | 2019-2023 | Spiriva Respimat, Combivent Respimat, Stiolto Respimat |
| Pharming Healthcare, INC. | $10,241.41 | 2019-2025 | Joenja, Ruconest |
| Novartis Pharmaceuticals Corporation | $6,769.50 | 2019-2025 | |
| Regeneron Pharmaceuticals, INC. | $3,608.93 | 2023-2024 | Dupixent |
| Genentech USA, INC. | $2,967.63 | 2019-2024 | Xolair |
| Glaxosmithkline, LLC. | $2,427.16 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Dermavant Sciences, INC. | $2,089.48 | 2023-2024 | Vtama |
| Csl Behring | $1,599.71 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Sanofi US Services INC. | $1,527.73 | 2025 | |
| Biocryst US Sales Co., LLC | $1,464.01 | 2021-2025 | Orladeyo |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $1,035.71 | 2019 | |
| Abbvie INC. | $883.70 | 2021-2025 | |
| Pfizer INC. | $840.50 | 2019-2025 | |
| Alk-Abello, INC | $778.03 | 2019-2024 | Grastek, Ragwitek, Odactra |
| Amgen INC. | $631.26 | 2020-2025 | Tezspire |
| Incyte Corporation | $524.51 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $489.80 | 2022-2025 | Adbry |
| Grifols USA, LLC | $452.86 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $409.04 | 2019-2022 | |
| Genentech, INC. | $288.80 | 2022-2024 | Xolair |
| Kaleo, INC. | $268.07 | 2019-2024 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $250.45 | 2019-2024 | |
| Adma Biomanufacturing LLC | $235.00 | 2021-2025 | |
| Bio Products Laboratory USA, INC. | $195.34 | 2020-2023 | Gammaplex, Coagadex |
| Mylan Specialty L.P. | $183.69 | 2021-2023 | Yupelri |
| Circassia INC. | $182.30 | 2019 | |
| Organon LLC | $132.55 | 2025 | Vtama |
| Grifols Shared Services North America, INC. | $113.41 | 2024 | Xembify |
| Optinose US, INC. | $112.58 | 2020-2024 | |
| Kyowa Kirin, INC. | $90.50 | 2025 | |
| Lilly USA, LLC | $80.43 | 2024-2025 | Ebglyss |
| Ionis Pharmaceuticals, INC. | $74.53 | 2025 | Dawnzera |
| Galderma Laboratories, L.P. | $56.78 | 2025 | Nemluvio |
| Kedrion Biopharma, INC. | $54.02 | 2024-2025 | Kedrab, Koate, Rhogam Ultra-Filtered Plus |
| Octapharma USA, INC. | $50.65 | 2023-2024 | Cutaquig |
| Biocryst Pharmaceuticals, INC. | $42.95 | 2020 | |
| Hospira, INC. | $34.69 | 2024-2025 | |
| Blueprint Medicines Corporation | $26.14 | 2023 | Ayvakit |
| Verona Pharma, INC. | $19.16 | 2025 | Ohtuvayre |
| Aimmune Therapeutics, INC. | $14.96 | 2021 | |
| Hikma Pharmaceuticals USA | $13.51 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pulin Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.